We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Metastases May Form Early in Development of Colorectal Cancer

By LabMedica International staff writers
Posted on 04 Jul 2019
Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). More...
Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time.

Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders. A new study suggests that many colorectal cancer metastases may have arisen and spread even before the primary tumor was large enough to be detected. Both the timing and molecular determinants of metastasis are unknown, hindering treatment and prevention efforts.

Scientists at Stanford University School of Medicine (Stanford, CA, USA) characterized the evolutionary dynamics of this lethal metastasis process by analyzing exome-sequencing data from 118 biopsies from 23 patients with colorectal cancer with metastases to the liver or brain. Through a phylogenetic analysis, the team traced the origins of these metastatic tumors. For all but one of the cases analyzed, they found the distant metastases corresponded to a monophyletic clade.

Within this cohort, the scientists noted high concordance among putative driver genes. Mutations in KRAS, TP53, SMAD4, and others were similar in primary and metastatic tumor pairs. In addition, primary and metastatic tumor pairs were also likely to share somatic single nucleotide variants (SNVs) and small indels. They noted most of these metastases actually diverged early in the emergence of the primary tumor. Most of the liver and all of the brain metastases harbored many private clonal somatic SNVs, but no subclonal ones. This indicated to the team that a single cell or a small group of genetically similar cells seed most metastases. They found that in their dataset 83%of the primary metastatic tumor pairs from 17 of the 21 patients likely underwent metastatic dissemination when the primary tumor was below the limits of clinical detection, which is smaller than 0.01 cm3 in size.

The scientists found in a separate cohort of 2,751 patients with colorectal cancer, including 938 patients with metastatic cancer, that most metastases harbored a set of core colorectal cancer driver genes, but also an additional candidate metastasis driver gene. In particular, they noted that the gene PTRT, a part of the STAT3 signaling pathway, appears to be a highly specific driver of metastasis. This suggested to them that early dissemination can occur in many colorectal cancer patients, underscoring the need for early detection, possibly through detecting cell-free tumor DNA as these small tumors fall at the limits of detection for imaging approaches. The study was published on June 17, 2019, in the journal Nature Genetics.

Related Links:
Stanford University School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Drug Testing Assays
Atellica DT 250 Analyzer
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.